Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

RTSL Revolutionizes CBD Vaping Industry with Convenient, Safe, and Economical FDA Listed CBD Inhaler Device

Company Summary

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) is an SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD and CBG.

Key Metrics @ 7/20/2020

Closing Price $0.9999
52 Week Range $0.21 to $2.00
Shares Outstanding 160.14M
Shares in the Float 19.16M
% Held by Insiders 89.89%
Shares Authorized 750M
Average Daily Volume: 30 Day 22,914
Market Cap $160.14M
Reporting Status SEC Reporting
Financials Audited
Most Recent Filing: 10-K  for 03/31/20 Filed:  06/29/2020
Fiscal Year-end 03/31

(Source: OTC Markets, Yahoo Finance, SEC filings)

Corporate News and Market Drivers

RTSL’s MDIs are a safe and technically superior replacement for vape pens, because they use no heat, function perfectly without using dangerous ingredients, and deliver a 98% bio-available dose of CBD and/or THC directly to the systemic blood stream. This allows RTSL to address the current U.S. vape market, which is estimated to be $5 billion in annual sales.

DALLAS, July 14, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD, CBG, and THC, announced today that it has delivered an additional 6,000 units (8,000 total) under its previously announced 100,000 unit order that was recently expanded to 250,000 units.    

DALLAS, July 09, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL), a fully-reporting, early stage, emerging biotech company focused on aerosol delivery of cannabinoids in the legal hemp and cannabis space using Metered Dose Inhalers (MDIs), announced today that RTSL has received an additional commitment of 150,000 units under a 100,000 unit wholesale order of its Rxoid™ brand 5.0 mg proprietary CBD/CBG formulation which delivers a 98% bio-available dose of CBD directly to the systemic blood stream.

RxoidTM Metered Dose Inhaler (MDI)

DALLAS, June 30, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (RTSL) an SEC fully-reporting, growth-oriented company focused on manufacturing and marketing aerosol delivery systems based on pressurized Metered Dose Inhaler (MDI) technology, announced today that it has executed a contract leasing a new state-of-the-art laboratory. The laboratory is being certified for manufacturing under Food and Drug Administration (FDA) rules.

Key Investment Highlights:

  • In 2019, vaping represented between 22% to 30% of the consumer market for CBD – (approximately $5B); total CBD market could be $23.6B by 2025
  • Pressurized Metered Dose Inhaler technology is FDA-listed, convenient, precise, safe – and largely obsolesces vaping
  • State of the art lab tested to ISO 6 standards and FDA Good Manufacturing Practices (GMP) related to ISO 13485 will allow RTSL to pursue FDA registration for all of its products
  • RTSL has contracted with an Industry-Leading digital marketing firm to launch a new consumer-focused product line in early Q3 CY 2020 to complement its RxoidTM brand which is primarily sold through medical practitioners and pharmacies
  • RTSL has the technology, marketing and management team to be a “key market leader” in CBD delivery systems

Personal Observation

In a coverage initiation report issued by Emerald Equity Research, Brian Connell, CFA on June 22, 2020, the analyst stated: “We rate the shares of RTSL a Strong Buy, and set our 12-Month Price Target at $2.30 per share, representing a One-year Gain of 411% (as of the close, June 19, 2020).

To view and download the report (at no cost) CLICK HERE.

RTSL has seen an upward movement from $0.45/share to $1.00 in the last 30 days. Based on the pro forma numbers I see in the Emerald report, I wouldn’t be surprised to see a $3.00 to $3.50 share price by EOY 2021… that’s a 300% to 350% uplift in price in just 18 months…!

Interested investors might want to keep RTSL on their radar screens or even start building a position in the shares.

By Mike Casson,

Executive Editor and Senior Analyst

_________________________________________________________________________

More About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

RTSL has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDIs) that contain and properly aerosolize proprietary formulae consisting of one or more cannabinoid compounds, such as CBD, CBG, and/or THC (only sold where legal).  The Company’s RxoidTM product line is manufactured in compliance with cGMP, on FDA approved equipment. Note that while non-THC Cannabinoids such as CBD and CBG are not yet approved by the FDA, under the laws of Texas and of many other states, it is legal to consume, sell and export them to legal jurisdictions.

Properly formulated MDIs deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient delivery method for an API other than an IV. In addition, MDIs are less expensive than any other route of delivery, based on the net cost per bioactive mg as tested in blood serum levels. MDIs are, however, expensive to formulate and difficult to manufacture in order to deliver cannabinoid compounds to the level required by the FDA and FTC truth in labelling laws.  Ideally, a properly formulated, properly manufactured MDI containing cannabinoids will deliver exactly the same dose on its first use as well as its 100th use.

RTSL markets its RxoidTM MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.  RTSL’s MDI products also can be purchased by consumers online, at www.rxoid.com.

Interested investors can find out more about Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) on the Company’s website at www.rtslco.com,

Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
[email protected]

Phone: 800-497-6059

Fax: 877-676-8527

www.rtslco.com

__________________________________________________________________________

Disclaimer and Disclosures: Green Leaf Investing, Green Leaf or GLI is a financial publisher and not a FINRA broker/dealer or investment adviser. Green Leaf is not registered with the SEC / U.S. Securities and Exchange Commission or any state securities regulatory agency. Readers, subscribers and web site visitors are responsible for individual investment decisions. All information contained in our newsletters or on our web site and in our blogs should be independently verified with the featured companies and readers should always conduct their own research and due diligence and engage professional investment advisers as they deem appropriate before making investment decisions. Please review the Terms and Conditions of Use, including without limitation all disclaimers of warranties and limitations on liability contained therein. Your use of any information on our websites, contained herein or in our newsletters and blogs constitutes your agreement of same. GLI did not receive any compensation for this article. However, officers, employees and affiliates may hold positions in the featured securities discussed in our newsletters or on our web site and blogs and may buy or sell said securities at any time without further notice. GLI and/or affiliates may from time to time receive cash and/or equity compensation from featured companies for corporate communications services. In the interest of full disclosure, Mike Casson, GLI’s Executive Editor is also president of Casson Communications, LLC (CCLLC) and Founder/Executive Editor of MicroCap MarketPlace, affiliated companies. CCLLC has received twenty-seven thousand two hundred fifty dollars in cash compensation from the subject company for corporate communication services and allocated a portion of that compensation for the distribution of this article as part of said services. You should be aware of these potential conflicts of interest. We believe the information contained herein and in our publications to be reliable but cannot guarantee its accuracy; therefore, all information is provided as is without warranty of any kind. Past results are not necessarily indicative of future performance.

SOURCE

Research and Editorial Staff

GreenLeafInvesting.org

© 2020 Green Leaf Investing, All Rights Reserved